Pance Katarina 4

What Happened
Katarina Pance, a director of Veradermics, Inc. (MANE), received a grant of 43,000 derivative securities on February 3, 2026. The reported acquisition price is $0.00, indicating an award of derivative instruments (e.g., stock options or similar) rather than an open‑market purchase. The filing shows no immediate cash outlay; the award becomes exercisable and fully vested on February 3, 2027 per the filing footnote.

Key Details

• Transaction date: 2026-02-03; Acquisition type: A (award/grant of derivative securities)
• Shares/units granted: 43,000; Reported acquisition price: $0.00 (derivative)
• Vesting/exercise note (F1): Fully vested and exercisable on Feb 3, 2027 (first anniversary of vesting commencement)
• Shares owned after transaction: Not specified in the provided filing excerpt
• Filing date: 2026-02-05 (filed within the typical 2-business-day Section 16 reporting window; not marked late)

Context
This was a derivative award—commonly a stock option or similar—that does not represent an immediate stock purchase. If and when exercised in the future, the award may require payment of an exercise price (not shown in the excerpt) to convert into common shares. Director equity awards are a common form of compensation and do not by themselves indicate buying or selling intent. For a full picture (total holdings, exercise price, expiration, and any restrictions), consult the complete Form 4 filing (Accession No. 0001193125-26-039876).